{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Company Reports", "name": "subject", "rank": "2", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/16/business/valeant-q4-financial-2016-guidance.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS", "contributor": "Gretchen Morgenson and Alexandra Stevenson contributed reporting."}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "813", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "pub_date": "2016-03-16T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "A Warning on Earnings by Valeant Sends Its Shares Into a Tailspin", "main": "Battered Valeant Stock Drops a Further 50% After Weak Guidance"}, "print_page": "1", "snippet": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "_id": "56e7f4b038f0d83d7cbf5024", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals shares drop over 50 percent after company releases earnings guidance and warns it may default on some of its debt; company says it now expects 2016 revenue of $11 billion to $11.2 billion, down from previous forecast of $12.5 billion to $12.7 billion.  "}